Navigation Links
Veran Medical Receives FDA Clearance to Market Electromagnetic Navigated Bronchoscopy Product: The SPiN Drive(TM) System
Date:12/8/2009

ST LOUIS, Dec. 8 /PRNewswire/ -- Veran Medical Technologies announced today that it received clearance (K091934) from the U.S. Food and Drug Administration (FDA) to market a product for the delivery of instruments through the pulmonary tract. "Veran is excited about this clearance as it allows the company to address a huge unmet clinical need in lung cancer diagnosis and treatment," said Jerome R. Edwards, Veran president and chief executive officer. "Leveraging our proprietary IG4 Platform Technology, currently on the market for percutaneous procedures, we are now able to launch our SPiN Drive(TM) System for endobronchial procedures."

Even without formal lung cancer screening, it is estimated that over 6 million Solitary Pulmonary Nodules (SPN's) are found each year in the US on chest CT scans. Lung Cancer is a deadly disease that fatally claims 85% of patients within five years. Many physicians believe the key to improved patient survival chances are linked to the definitive early diagnosis of lung cancer at Stage 1. However, SPN's in the peripheral lung are inaccessible with today's techniques and technologies, leaving patients on "watchful waiting" protocols of repeat CT scans for multiple years causing patient anxiety and significant costs added to the US Healthcare System.

Veran's SPiN Drive(TM) System acts as a GPS-like system to enable pulmonologists and surgeons to access these peripheral SPN's to immediately diagnose malignancy, stop the "watchful waiting" and reduce US Healthcare spending. Recently, the American Medical Association (AMA) issued a new Category 1 CPT code for the use of electromagnetic navigational bronchoscopy (ENB) devices to target to lesions or spots deep in the lungs. The company believes in the future that the SPiN Drive(TM) System may enable the delivery of several therapies to treat lung cancer at an early stage before it has spread to the lymphatic system when pati
'/>"/>

SOURCE Veran Medical Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Globus Medical Raises $110 Million in Series E Financing Round
6. Quark Pharmaceuticals Appoints New Chief Medical Officer
7. Boston University Biomedical Engineers Find Chink in Bacterias Armor
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
10. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
11. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Corporation (NASDAQ: CYTR ), a biopharmaceutical research and ... for the three months ended June 30, 2015, and ... milestones for its clinical development programs. "The ... CytRx. Enrollment in our ongoing pivotal global Phase 3 ... continues on track to be completed in the first ...
(Date:8/3/2015)... 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) ... Quarter 2015 Investor Conference Call and webcast at 4:30 p.m., ... call will cover an update on Merrimack,s progress as ... A press release detailing the information to be discussed ... Monday, August 10. Investors and the general public are ...
(Date:8/3/2015)... Aug. 3, 2015  Celsion Corporation (NASDAQ: ... host a conference call to discuss its second ... on its development programs for ThermoDox®, its proprietary ... acquired technology platforms, TheraPlas™ and TheraSilence™, in immunotherapy ... Monday, August 10, 2015. To participate in the ...
Breaking Medicine Technology:CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015 2
... 29, 2011 Robbins & Myers, Inc. ... sale of its Romaco businesses to a group of ... private equity investment firm.  Total consideration was approximately euro ... of cash and euro 4 million of assumed liabilities ...
... SILVER SPRING, Md., April 29, 2011 Don,t let expired ... dispose of them properly to prevent them from harming others. ... part in the second annual National Prescription Drug Take-Back Day, ... View a slideshow and read a Consumer Update ...
Cached Medicine Technology:
(Date:8/4/2015)... ... August 04, 2015 , ... The Law Offices of Ben C. ... claims dealing with Inferior Vena Cava Filters (“IVC Filters”). , As lead IVC filter ... Cook IVC Filter clients under In re Cook Medical, Inc., IVC Filters Marketing, Sales ...
(Date:8/4/2015)... ... August 04, 2015 , ... In the most recent ... & Johnson report that a new location for pretrial proceedings is under consideration, ... and cancer warning information at their website, the Talcum Powder Cancer Lawsuit Center. ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... independent educational grants in support of an interaction simulation session entitled "NOACS: What ... is jointly provided by Medical Learning Institute Inc. and EDUmotion US LLC. , ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... press at its Denver facility that will usher in a new standard of ... Lightning Labels more effectively meet its twin objectives of quality and quantity ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... "The Winscribe Text results have been impressive so far". , Mr Cauchois ... management from Winscribe's French sales partner Dicma and the healthcare technology offered by ...
Breaking Medicine News(10 mins):Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 2Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 3Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 2Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 4
... in the middle ear, a condition called otitis media with ... antihistamines and decongestants, a new review of studies has found.// ... alleviating symptoms or avoiding complications of OME and expose children ... ,"This review finds no benefit for any of the short- ...
... the hepatitis C virus during the first part of 1990, ... hospital which was not sufficiently screened for safety. ,Following ... test for Hepatitis C came out into the open. ... screening for any liver condition. ,The Labor Party's ...
... exploits are titillated by personality traits, contemplates a new ... The idea that personality types may increase the susceptibility ... ,Researchers at the University of Chicago have ... for cancer as compared to the rats that portrayed ...
... researchers, stress among youth associated with parental separation and ... at the John Moores University in Liverpool have found ... parents in recognizing the physical and emotional changes in ... and mental health. ,According to them, there ...
... exhaust of diesel trucks constitute a major contributor to ... children// in the South Bronx, according to the results ... University’s School of Medicine and Robert F. Wagner Graduate ... the study, asthma symptoms, particularly wheezing, doubled among elementary ...
... have found the brain’s natural antioxidant defense mechanism to ... ,According to the researchers at the Dana-Farber Cancer ... harmful effects of toxic ‘free radicals’ that are the ... with aging and certain degenerative brain diseases, heart attack, ...
Cached Medicine News:Health News:Allergy Drugs More Harmful Than Helpful for Chronic Ear Inflammation 2Health News:Allergy Drugs More Harmful Than Helpful for Chronic Ear Inflammation 3Health News:Stress brings about early onset of puberty 2Health News:Asthma Symptoms Linked to Soot from Diesel Trucks in So. Bronx 2Health News:Asthma Symptoms Linked to Soot from Diesel Trucks in So. Bronx 3
The TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in native coronary arteries = 2.5 to = 3....
... Maximum, Maximum Xtra, and Maximum ACT ... standard and specialty hemostasis introducers in ... the premier hemostasis introducers for use ... including angiography, angioplasty, stenting, atherectomy, temporary ...
St. Jude Medical's line of guiding introducers includes Swartz Series, SAFL, SEPT, CSTA, RAMP, and 2 piece steerable...
Rapid Exchange Stent Delivery System with Hepacoat...
Medicine Products: